Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Euroapi Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Euroapi's earnings have been declining at an average annual rate of -79.7%, while the Pharmaceuticals industry saw earnings growing at 14% annually. Revenues have been declining at an average rate of 2.2% per year.
Anahtar bilgiler
-79.7%
Kazanç büyüme oranı
-79.6%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 16.3% |
| Gelir büyüme oranı | -2.2% |
| Özkaynak getirisi | -32.3% |
| Net Marj | -29.6% |
| Sonraki Kazanç Güncellemesi | 11 Feb 2025 |
Yakın geçmiş performans güncellemeleri
Recent updates
There's No Escaping Euroapi S.A.'s (EPA:EAPI) Muted Revenues Despite A 32% Share Price Rise
Jul 29
Euroapi S.A. (EPA:EAPI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
May 24Euroapi (EPA:EAPI) Seems To Be Using A Lot Of Debt
Apr 10Little Excitement Around Euroapi S.A.'s (EPA:EAPI) Revenues As Shares Take 31% Pounding
Mar 03Euroapi S.A. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
Mar 02A Look At The Fair Value Of Euroapi S.A. (EPA:EAPI)
Dec 21Analysts Are Updating Their Euroapi S.A. (EPA:EAPI) Estimates After Its Half-Yearly Results
Aug 04Is Euroapi S.A. (EPA:EAPI) Trading At A 49% Discount?
Aug 02Euroapi S.A.'s (EPA:EAPI) Subdued P/S Might Signal An Opportunity
Jun 16An Intrinsic Calculation For Euroapi S.A. (EPA:EAPI) Suggests It's 37% Undervalued
Jan 25Euroapi S.A.'s (EPA:EAPI) Intrinsic Value Is Potentially 38% Above Its Share Price
Oct 15Statutory Profit Doesn't Reflect How Good Euroapi's (EPA:EAPI) Earnings Are
Sep 09Gelir ve Gider Dağılımı
Euroapi nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 971 | -287 | 135 | 30 |
| 31 Mar 24 | 995 | -238 | 134 | 30 |
| 31 Dec 23 | 1,019 | -190 | 134 | 30 |
| 30 Sep 23 | 1,006 | -79 | 135 | 27 |
| 30 Jun 23 | 994 | 31 | 137 | 24 |
| 31 Mar 23 | 987 | 8 | 133 | 23 |
| 31 Dec 22 | 981 | -15 | 129 | 22 |
| 30 Sep 22 | 962 | -3 | 120 | 20 |
| 30 Jun 22 | 944 | 10 | 110 | 18 |
| 31 Mar 22 | 918 | 1 | 100 | 18 |
| 31 Dec 21 | 893 | -8 | 90 | 17 |
| 31 Dec 20 | 945 | -6 | 71 | 20 |
| 31 Dec 19 | 916 | 3 | 66 | 16 |
Kaliteli Kazançlar: EAPI is currently unprofitable.
Büyüyen Kar Marjı: EAPI is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: EAPI is unprofitable, and losses have increased over the past 5 years at a rate of 79.7% per year.
Büyüme Hızlandırma: Unable to compare EAPI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: EAPI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-19.9%).
Özkaynak Getirisi
Yüksek ROE: EAPI has a negative Return on Equity (-32.3%), as it is currently unprofitable.